Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.

ABSTRACT:

Objective

To assess neurocognitive outcomes following antipsychotic intervention in youth enrolled in the National Institute of Mental Health (NIMH)-funded Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS).

Method

Neurocognitive functioning of youth (ages 8 to 19 years) with schizophrenia or schizoaffective disorder was evaluated in a four-site, randomized, double-blind clinical trial comparing molindone, olanzapine, and risperidone. The primary outcomes were overall group change from baseline in neurocognitive composite and six domain scores after 8 weeks and continued treatment up to 52 weeks. Age and sex were included as covariates in all analyses.

Results

Of 116 TEOSS participants, 77 (66%) had post-baseline neurocognitive data. No significant diff

SUBMITTER: Frazier JA 

PROVIDER: S-EPMC3337647 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature